Summary
The vitamin B-6 status (α-EGOT, PLP in erythrocytes) is impaired in patients with gynecological cancer (cervix uteri, endometrium, ovary and breast), mainly in patients with stage II and III uterine and ovarian carcinomas. We compared the occurrence of 3 important prognostic factors, undifferentiated malignant tumor patients with oestrogen-progesterone-poor receptor status, tumor grading, ploidy status and the epidermal growth factor (EGF) in these patients with the vitamin B-6 status before the beginning of therapy. We found that the low PLP values before treatment were also a prognostic factor for poor survival or the occurrence of distant metastases. Similar to our findings about the lack of influence of chemotherapy on vitamin B-6 and B-1 metabolism, we also found no changes in the vitamin B-6 and B-1 values, (EGOT, PLP and ETK) in 39 patients with gynecological carcinoma during hormone therapy. Only tumor progression caused the vitamin B-6 deficiency in these female tumor patients.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Bauknecht T, Rau B, Meerpohl H, Pfleiderer A. The prognostic value of the presence of EGF receptors in ovarian carcinomas. Tumor Diagn Ther 1984; 5: 62–66.
Bauknecht T, Kiechle M, Bauer G, Siebers J. Characterization of growth factors in human ovarian carcinomas. Cancer Res 1986; 46: 2614–2618.
Bauknecht T, Runge M, Schwall M, Pfleiderer A. Occurrence of epidermal growth factor receptors (EGF-R) in human adnexal tumors and their prognostic value in advanced ovarian carcinomas. Gynecol Oncol 1988; 29: 147–159.
Bender DA. Oestrogens and vitamin B-6 actions and interactions. World Rev Nutr Diet 1987; 51: 140.
Bunce GE, Vessai M. Effect of zinc and/or pyridoxine deficiency upon oestrogen retention and oestrogen receptor distribution in the rat uterus. J Steroid Biochem 1987; 26: 303.
Carpenter G, Cohen S. Epidermal growth factors. Ann Rev Biochem 1979; 48: 193–216.
Creasman WT, Sasso RA, Weed JC, McCartey KS. Ovarian carcinoma: histologic and clinical correlation of cytoplastic estrogen and progesterone binding. Gynecol Oncol 1981; 12: 319–327.
DeVita VT, Chabner BA, Livingston DM, Oliverio VT. Anergy and tryptophan metabolism in Hodgkin’s disease. Am J Clin Nutr 1971; 24: 835–840.
Friedlander ML, Hedley DW, Taylor IW, Russell P, Coates AS, Tattersall MNH. Influence of cellular DNA content on survival in advanced ovarian cancer. Cancer Res 1984; 44: 397–400.
Ladner H-A, Lieser H. Zum Vitamin B-6-Stoffwechsel während der gynäkologischen Strahlentherapie. Radiologe 1972; 12: 240–242.
Ladner H-A, Salkeld RM. Vitamin B-6 status and administration during radiation therapy. In: Meyskens FL, jr, Prasad KN, eds. Vitamins and cancer. Clifton, New Jersey: Humana Press, 1986: 429–437.
Ladner H-A, Salkeld RM. Vitamin B-6 status in cancer patients: Effect of tumour site, irradiation, hormones and chemotherapy. In: Tryfiates GP, Prasad KN, eds. Nutrition, growth, and cancer. New York: Alan R Liss, 1988: 273–281.
Leklem JE, Brown RR, Potera C, Becker DS. A role for vitamin B-6 in cancer. In: Van Eys et al, eds. Nutrition and cancer. New York: SP Medical and Scientific Books, 1979.
Litwack G, Miller-Diener A, DiSorbo DM, Schmidt TJ. In: Reynolds RD, Leklem JE, eds. Vitamin B-6: its role in health and disease. New York: Alan R Liss, 1985: 177–191.
Pfleiderer A, Kleine W, König P, Geyer H. Hormonal receptors in endometrial cancer, analysis of clinical prognosis and risk factors. In: Wolff JP, Scott JS, eds. Hormones and sexual factors in human cancer aetiology. Amsterdam: Elsevier Science Publ BV, 1984: 35–46.
Perheentupa J, Lakshmanan J, Hoath SB, Fisher DA. Hormonal modulation of mouse plasma concentration of epidermal growth factor. Acta encocrinol 1987; 107: 571–576.
Potera C, Rose DP, Brown RR. Vitamin B-6 deficiency in cancer patients. Am J Clin Nutr 1977; 30: 1677–1679.
Quinn MA, Pearce P, Rome R, Funder JW, Fortune D, Pepperell RJ. Cytoplasmic steroid receptors in ovarian tumours. Brit J Obstet Gynecol 1982; 89: 754–759.
Sainsbury J, Farndon J, Needham G, Malcolm A, Harris A. Epidermal growth factor receptor status as predictor of early recurrence and death from breast cancer. Lancet 1987; I: 1398.
Schwartz PE, Livolsi VA, Hildreth N, MacLusky NJ, Naftolin FN, Eisenfeld AJ. Estrogen receptors in ovarian epithelial carcinoma. Obstet Gynecol 1982; 59: 229–238.
Talbott MC, Miller LT, Kerkvliet NI. Pyridoxine supplementation: effect on lymphocyte responses in elderly persons. Am J Clin Nutr 1987; 46: 659.
Vuilleumier JP, Keller HE, Rettenmaier R, Hunziker F. Clinical chemical methods for the routine assessment of the vitamin status in human populations. Part II: The water-soluble vitamins B-1, B-2 and B-6. Int J Vitam Nutr Res 1983; 53: 259–270.
Zetterberg A, Esparti PL. Prognostic significance of nuclear DNA levels in prostatic carcinoma. Scand J Urol Nephrol 1980; 55 (suppl): 53–59.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1990 The Humana Press Inc.
About this chapter
Cite this chapter
Ladner, HA., Salkeld, R.M. (1990). Vitamin B-6 and B-1 Status during Hormone Therapy of Gynecological Cancer. In: Prasad, K.N., Meyskens, F.L. (eds) Nutrients and Cancer Prevention. Experimental Biology and Medicine, vol 23. Humana Press. https://doi.org/10.1007/978-1-4612-4516-2_22
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4516-2_22
Publisher Name: Humana Press
Print ISBN: 978-1-4612-8856-5
Online ISBN: 978-1-4612-4516-2
eBook Packages: Springer Book Archive